BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - BioCryst Pharmaceuticals reported a quarterly loss of $0.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.24, but an improvement from a loss of $0.38 per share a year ago [1] - The company achieved revenues of $93.4 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 4.72% and up from $79.55 million year-over-year [1] - Over the last four quarters, BioCryst has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $85.97 million, and for the current fiscal year, it is -$0.67 on revenues of $406.94 million [4] - The estimate revisions trend for BioCryst is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [4] Industry Context - The Medical - Drugs industry, to which BioCryst belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [5] - Rigel Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.04 per share, reflecting a significant year-over-year decline of 500%, with revenues projected at $33.5 million, down 34.7% from the previous year [5]